Form 4: Acrivon Therapeutics Insider Sells Shares

Mary Miller, Chief Legal Officer at Acrivon Therapeutics, reported a transaction involving the sale of common stock.

Summary

• Mary Miller, Chief Legal Officer of Acrivon Therapeutics, Inc., reported a transaction on May 14, 2026.
• The transaction involved the withholding of 184 shares of common stock by the Issuer to satisfy mandatory tax withholding requirements upon the vesting of restricted stock units.
• Following this transaction, Ms. Miller beneficially owns 32,937 shares of common stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as the transaction is a standard tax withholding event and does not indicate a change in the insider's fundamental view of the company.

Negatives

• Insider selling can sometimes be interpreted as a lack of confidence in the company's future prospects, although in this case it is for tax withholding.

Future Outlook

No specific future outlook or guidance is provided in this filing.

Industry Context

StockSavvy.ai notes that Form 4 filings are routine disclosures of insider transactions and, in this instance, the transaction appears to be a standard tax withholding event related to equity compensation, rather than a strategic decision to divest shares.

Stakeholder Impact

• Shareholders: The transaction is a standard tax withholding event and is not expected to have a significant impact on the share price or overall shareholder value.

Key Dates

Keywords

Acrivon Therapeutics, ACRV, Form 4, Insider Transaction, Stock Withholding, Tax Withholding, Chief Legal Officer